Cancer Treatment Reviews
Volume 30, Issue 3 , Pages 249-253 , May 2004

The evidence-based treatment of AIDS-related non-Hodgkin’s lymphoma

  • Justin Stebbing

      Affiliations

    • Medical Day Unit, Department of Oncology, Chelsea & Westminster Hospital, 369 Fulham Road, London SW10 9NH, UK
    • ,
  • Vanessa Marvin

      Affiliations

    • Pharmacy Department, Royal Surrey County Hospital, Guildford, Surrey, UK
    • ,
  • Mark Bower

      Affiliations

    • Medical Day Unit, Department of Oncology, Chelsea & Westminster Hospital, 369 Fulham Road, London SW10 9NH, UK
    • Corresponding Author InformationCorresponding author. Tel.: +44-181-237-5054; fax: +44-181-746-8863

References 

  1. Dal Maso L, Franceschi S. Epidemiology of non-Hodgkin lymphomas and other haemolymphopoietic neoplasms in people with AIDS. Lancet Oncol. 2003;4(2):110–119
  2. International collaboration on HIV and Cancer. Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults. J Natl Cancer Inst 2000;92(22):1823–30
  3. Fong IW, Ho J, Toy C, Lo B, Fong MW. Value of long-term administration of acyclovir and similar agents for protecting against AIDS-related lymphoma: case-control and historical cohort studies. Clin. Infect. Dis. 2000;30:757–761
  4. Matthews G, Bower M, Mandalia S, Powles T, Nelson M, Gazzard B. Changes in acquired immunodeficiency syndrome-related lymphoma since the introduction of highly active antiretroviral therapy. Blood. 2000;96:2730–2734
  5. Grulich AE, Wan X, Law MG, Milliken ST, Lewis CR, Garsia RJ, et al.  B-cell stimulation and prolonged immune deficiency are risk factors for non-Hodgkin’s lymphoma in people with AIDS. AIDS. 2000;14:133–140
  6. Kaplan LD, Abrams DI, Feigal E, McGrath M, Kahn J, Neville P, et al.  AIDS-associated non-Hodgkin’s lymphoma in San Francisco. J. Am. Med. Assoc. 1989;261(5):719–724
  7. Levine AM, Sullivan Halley J, Pike MC, Rarick MU, Loureiro C, Bernstein Singer M, et al.  Human immunodeficiency virus-related lymphoma. Prognostic factors predictive of survival. Cancer. 1991;68(11):2466–2472
  8. Rossi G, Donisi A, Casari S, Re A, Cadeo G-P, Carosi G. The International Prognostic Index can be used as a guide to treatment decisions regarding patients with human immunodeficiency virus-related non-Hodgkin lymphoma. Cancer. 1999;86:2391–2397
  9. Straus DJ, Huang J, Testa MA, Levine AM, Kaplan LD. Prognostic factors in the treatment of human immunodeficiency virus-associated non-Hodgkin’s lymphoma: analysis of AIDS Clinical Trials Group protocol 142–low-dose versus standard-dose m-BACOD plus granulocyte-macrophage colony-stimulating factor. J. Clin. Oncol. 1998;16:3601–3606
  10. Kaplan LD, Straus DJ, Testa MA, Von Roenn J, Dezube BJ, Cooley TP, et al.  Low dose compared with standard dose m-BACOD chemotherapy for non-Hodgkin’s lymphoma associated with human immunodeficiency virus infection. N. Engl. J. Med. 1997;336:1641–1648
  11. Tirelli U. Dose adjusted treatment in AIDS-related lymphoma. J. Acq. Immunodef. Synd. 2000;23:A12
  12. Navarro JT, Ribera JM, Oriol A, Vaquero M, Romeu J, Battle M, et al.  Influence of highly active anti-retroviral therapy on response to treatment and survival in patients with acquired immunodeficiency syndrome-related non-Hodgkin’s lymphoma treated with cyclophosphamide, hydroxydoxorubicin, vincristine and prednisone. Br. J. Haematol. 2001;112(4):909–915
  13. Vaccher E, Spina M, di Gennaro G, Talamini R, Nasti G, Schioppa O, et al.  Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma. Cancer. 2001;91(1):155–163
  14. Sparano JA, Wiernik PH, Strack M, et al.  Infusional cyclophosphamide, doxorubicin and etoposide in HIV and HTLV-1 related non Hodgkin’s lymphoma. Blood. 1993;81:2810–2815
  15. Sparano JA, Wiernik PH, Hu X, Sarta C, Schwartz EL, Soeiro R, et al.  Pilot trial of infusional cyclophosphamide, doxorubicin and etoposide plus didanosine and filgrastim in patients with HIV associated non-Hodgkin’s lymphoma. J. Clin. Oncol. 1996;14:3026–3035
  16. Sparano JA, Wiernik PH, Hu X, Sarta H, Henry DH, Ratech H. Saquinavir enhances the mucosal toxicity of infusional cyclophosphamide, doxorubicin and etoposide in patients with HIV-associated non-Hodgkin’s lymphoma. Med. Oncol. 1998;15:50–57
  17. Sparano JA, Weller E, Nazeer T, Habermann T, Traynor AE, Manalo J, et al.  Phase 2 trial of infusional cyclophosphamide, doxorubicin, and etoposide in patients with poor-prognosis, intermediate-grade non-Hodgkin lymphoma: an Eastern Cooperative Oncology Group trial (E3493). Blood. 2002;100(5):1634–1640
  18. Little RF, Pearson D, Steinberg S, Elwood PE, Yarchoan R, Wilson WH. Dose-adjusted EPOCH chemotherapy in previously untreated HIV-associated non-Hodgkin’s lymphoma. Proc Am Soc Clin Oncol 1999;18:10a
  19. Little RF, Pittaluga S, Grant N, Steinberg SM, Kavlick MF, Mitsuya H, et al.  Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology. Blood. 2003;
  20. Tirelli U, Spina M, Jaeger U, Nigra E, Blanc PL, Liberati AM, et al.  Infusional CDE with rituximab for the treatment of human immunodeficiency virus-associated non-Hodgkin’s lymphoma: preliminary results of a phase I/II study. Recent Results Cancer Res. 2002;159:149–153
  21. Boue F, Gabarre J, Gisselbrecht C, Reynes J, Plantier I, Morlat P, et al. CHOP chemotherapy plus Rituximab in HIV patients with high grade lymphoma – results of an ANRS Trial. Proc ASH 2003 [Abst 1824]
  22. Kaplan LD, Scadden DT, for the AIDS malignancies consortium. No benefit from rituximab in a randomized phase III trial of CHOP with or without rituximiab for patients with HIV-associated non-Hodgkin’s lymphoma: AIDS malignancies consortium study 010. Proc Am Soc Clin Oncol 2003;22:564 [Abstract]
  23. Levine AM, Espina BM, Yuzon R, Sanchez MN, Dharmapala D, Gill PS, et al.  Treatment of relapsed/refractory AIDS related lymphomas with high dose cytarabine/cisplatin combination regimens. J. Acq. Immunodef. Synd. 2000;23:A24
  24. Kentos A, Vekemans M, Van Vooren JP, Lambermont M, Liesnard C, Feremans W, et al.  High-dose chemotherapy and autologous CD34-positive blood stem cell transplantation for multiple myeloma in an HIV carrier. Bone Marrow Transplant. 2002;29(3):273–275
  25. Krishnan A, Molina A, Zaia J, Nademanee A, Kogut N, Rosenthal J, et al.  Autologous stem cell transplantation for HIV-associated lymphoma. Blood. 2001;98(13):3857–3859
  26. Molina A, Krishnan AY, Nademanee A, Zabner R, Sniecinski I, Zaia J, et al.  High dose therapy and autologous stem cell transplantation for human immunodeficiency virus-associated non-Hodgkin lymphoma in the era of highly active antiretroviral therapy. Cancer. 2000;89(3):680–689
  27. Gabarre J, Azar N, Autran B, Katlama C, Leblond V. High-dose therapy and autologous haematopoietic stem-cell transplantation for HIV-1-associated lymphoma. Lancet. 2000;355(9209):1071–1072
  28. Campbell P, Iland H, Gibson J, Joshua D. Syngeneic stem cell transplantation for HIV-related lymphoma. Br. J. Haematol. 1999;105(3):795–798
  29. Gabarre J, Leblond V, Sutton L, Azar N, Jouan M, Boccaccio C, et al.  Autologous bone marrow transplantation in relapsed HIV-related non-Hodgkin’s lymphoma. Bone Marrow Transplant. 1996;18(6):1195–1197
  30. Bower M, Fife K, Sullivan A, Kirk S, Phillips RH, Nelson M, et al.  Treatment outcome in presumed and confirmed AIDS-related primary cerebral lymphoma. Eur. J. Cancer. 1999;35(4):601–604
  31. Baumagartner JE, Rachlin JR, Beckstead JH, Meeker TC, Levy R, Wara WM, et al.  Primary central nervous system lymphomas: natural history and response to radiation therapy in 55 patients with acquired immunodeficiency syndrome. J. Neurosurg. 1990;73(2):206–211
  32. Jacomet C, Girard PM, Lebrette MG, Farese VL, Monfort L, Rozenbaum W. Intravenous methotrexate for primary central nervous system non-Hodgkin’s lymphoma in AIDS. AIDS. 1997;11:1725–1730

PII: S0305-7372(03)00216-0

doi: 10.1016/j.ctrv.2003.12.004

Cancer Treatment Reviews
Volume 30, Issue 3 , Pages 249-253 , May 2004

Article Tools